Brief: Pulse Biosciences Announces FDA 510(K) Clearance For The Treatment Of Sebaceous Hyperplasia
26/09/2022 13:27
Sept 26 (Reuters) - Pulse Biosciences Inc PLSE.O :
* PULSE BIOSCIENCES ANNOUNCES FDA 510(K) CLEARANCE FOR THE
TREATMENT OF SEBACEOUS HYPERPLASIA
Source text for Eikon: ID:nBw7FjDZya
Further company coverage: PLSE.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Pulse Biosciences
See all newsBrief: Pulse Biosciences, Inc. Announces Planned Redemption Of Warrants
Chairmen Total Approximately $13.3 Million
Pulse Biosciences records Q1 revenue, but loss widens on higher clinical investment
Brief: Pulse Biosciences Q1 Net Income USD -18.581 Million
Brief: Pulse Biosciences Announces Positive Clinical Data From Npulse Cardiac Catheter System